| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
2-Methylthio-ADP trisodium salt | 475193-31-8 | sc-203464 | 10 mg | $838.00 | 5 | |
2-Methylthio-ADP trisodium salt is a selective agonist for P2Y1 receptors, distinguished by its unique methylthio modification that enhances binding affinity. This compound initiates distinct signaling cascades, influencing platelet activation and vascular responses. Its trisodium salt form improves solubility and stability, allowing for efficient interaction with cellular membranes. The compound's kinetic profile supports rapid receptor activation, making it a key player in purinergic signaling dynamics. | ||||||
BzATP triethylammonium salt | 112898-15-4 | sc-203862 | 5 mg | $156.00 | 4 | |
BzATP triethylammonium salt serves as a potent P2Y1 receptor agonist, characterized by its triethylammonium moiety that enhances membrane permeability and receptor engagement. This compound triggers specific intracellular signaling pathways, leading to calcium mobilization and cellular responses. Its unique structure promotes rapid kinetics, facilitating swift receptor activation and downstream effects. The compound's solubility profile further supports effective interactions with lipid bilayers, optimizing its bioavailability in various environments. | ||||||
NF 546 | 1006028-37-0 | sc-361275 sc-361275A | 10 mg 50 mg | $550.00 $2000.00 | ||
NF546 is a selective P2Y11 agonist but also shows activity at P2Y1 receptors, highlighting the complexity of P2Y receptor pharmacology. | ||||||
NF 157 | 104869-26-3 | sc-204125 sc-204125A | 1 mg 5 mg | $500.00 $2040.00 | 1 | |
NF157 is primarily a P2Y11 antagonist but can modulate P2Y1 receptor activity indirectly through its effects on related signaling pathways. | ||||||
Adenosine Kinase Inhibitor Inhibitor | 214697-26-4 | sc-202900 | 5 mg | $443.00 | 9 | |
Adenosine Kinase Inhibitor can increase extracellular adenosine levels, indirectly modulating P2Y1 receptor activity through adenosine receptor pathways. | ||||||